Concepedia

Publication | Open Access

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

373

Citations

14

References

2023

Year

Abstract

Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease. (Funded by AbbVie; U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.).

References

YearCitations

Page 1